2-(4-benzyloxy-phenoxy)-2-methyl-butyric acid ethyl ester | 851125-26-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-benzyloxy-phenoxy)-2-methyl-butyric acid ethyl ester
• 英文别名: ethyl 2-methyl-2-(4-phenylmethoxyphenoxy)butanoate
• CAS: 851125-26-3
• 化学式: C₂₀H₂₄O₄
• 分子量: 328.408
• InChiKey: PUWXPIVPXJEUSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-benzyloxy-phenoxy)-2-methyl-butyric acid ethyl ester 在 钯 作用下， 以 乙酸乙酯 为溶剂， 反应 5.0h， 生成 2-(4-羟基苯氧基)-2-甲基丁酸乙酯
  参考文献：
  名称：

  Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them

  摘要：

  本发明涉及公式（I）的新化合物及其药学上可接受的盐，其中环“Ar1”表示单环或多环芳香或部分饱和芳香多环，可选含有最多3个选自N、S或O的杂原子。所述的单环或多环环可以未取代或具有最多4个相同或不同的取代基；m和n分别表示0到6的整数；A表示O、S或键；Y选自（CH2）p′（CH2）pB（CH2）q′（CH2）rB（CH2）pD（CH2）p′，其中p、q和r各自独立地表示0到6的整数；B和D分别表示S、O、NR4或键，条件是当B和D表示杂原子时，p不为零；R4表示氢、烷基、烯基、—S（O）2—R8或—C（O）R8，其中R8为烷基、烷氧基；R5和R6各自独立地表示氢、烷基、环烷基或烷氧基；R5和R6可以一起形成3-8成员环，该环可以选择性地包含选自O、S或N的一个或两个杂原子；R7表示氢、可选地从烷基、环烷基、烯基或炔基中选择的取代基。本发明还涉及公式（I）化合物的制备方法，含有公式（I）化合物的制药组合物以及其作为抗糖尿病、降脂、抗肥胖和降胆固醇药物的应用。

  公开号：

  US20070093476A1

文献信息

• [EN] NOVEL COMPOUNDS AND THEIR USE AS ANTIDIABETIC AND HYPOLIPIDEMIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES ET LEUR UTILISATION EN MEDECINE, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：REDDYS LAB LTD DR

  公开号：WO2005040102A3

  公开（公告）日：2006-03-23
• NOVEL COMPOUNDS AND THEIR USE AS ANTIDIABETIC AND HYPOLIPIDEMIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Dr. Reddy's Laboratories Ltd.

  公开号：EP1680397A2

  公开（公告）日：2006-07-19
• [EN] NOVEL COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES ET LEUR UTILISATION EN MEDECINE, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：REDDYS LAB LTD DR

  公开号：WO2005040102A2

  公开（公告）日：2005-05-06

  The present invention relates to novel compounds of formula (I) and their pharmaceutically acceptable salts, wherein ring “Ar1” represents a monocyclic or polycyclic aromatic or partially saturated aromatic polycyclic, which may optionally contain up to 3 heteroatoms selected from N, S or O. The said monocyclic or polycyclic ring may be unsubstituted or have up to 4 substituents which may be identical or different; m and n independently represents an integer from 0 to 6; A represents O, S or bond; Y is selected from (CH2)p’ (CH2)pB(CH2)q’ (CH2)rB(CH2)pD(CH2)q’ where p, q and r each independently represents an integer from 0 to 6; B and D independently represents S, O, NR4 or a bond, with a proviso that when B and D represents hereto atom p is not zero; R4 represents hydrogen, alkyl, alkenyl, -S(O)2-R8 or -C(O)R8 where R8 is alkyl, alkoxy; R5 and R6 independently represents hydrogen, alkyl, cycloalkyl or alkoxy; R5 and R6 together may form 3-8 membered cyclic ring which may optionally contains one or two hereto atoms selected from O, S or N; R7 represents hydrogen, optionally substituted groups selected form alkyl, cycloalkyl, alkenyl or alkynyl. The present invention also relates to a process for preparation of compounds of formula (I), to pharmaceutical compositions containing compounds of formula (I) and their use in particular as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic agents.
• Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
  申请人：Debnath Bhunia

  公开号：US20070093476A1

  公开（公告）日：2007-04-26

  The present invention relates to novel compounds of formula (I) and their pharmaceutically acceptable salts, wherein ring “Ar 1 ” represents a monocyclic or polycyclic aromatic or partially saturated aromatic polycyclic, which may optionally contain up to 3 heteroatoms selected from N, S or O. The said monocyclic or polycyclic ring may be unsubstituted or have up to 4 substituents which may be identical or different; m and n independently represents an integer from 0 to 6; A represents O, S or bond; Y is selected from (CH 2 ) p′ (CH 2 ) p B(CH 2 ) q′ (CH 2 ) r B(CH 2 ) p D(CH 2 ) p′ where p, q and r each independently represents an integer from 0 to 6; B and D independently represents S, O, NR 4 or a bond, with a proviso that when B and D represents hereto atom p is not zero; R 4 represents hydrogen, alkyl, alkenyl, —S(O) 2 —R 8 or —C(O)R 8 where R 8 is alkyl, alkoxy; R 5 and R 6 independently represents hydrogen, alkyl, cycloalkyl or alkoxy; R 5 and R 6 together may form 3-8 membered cyclic ring which may optionally contains one or two hereto atoms selected from O, S or N; R 7 represents hydrogen, optionally substituted groups selected form alkyl, cycloalkyl, alkenyl or alkynyl. The present invention also relates to a process for preparation of compounds of formula (I), to pharmaceutical compositions containing compounds of formula (I) and their use in particular as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic agents.

  本发明涉及公式（I）的新化合物及其药学上可接受的盐，其中环“Ar1”表示单环或多环芳香或部分饱和芳香多环，可选含有最多3个选自N、S或O的杂原子。所述的单环或多环环可以未取代或具有最多4个相同或不同的取代基；m和n分别表示0到6的整数；A表示O、S或键；Y选自（CH2）p′（CH2）pB（CH2）q′（CH2）rB（CH2）pD（CH2）p′，其中p、q和r各自独立地表示0到6的整数；B和D分别表示S、O、NR4或键，条件是当B和D表示杂原子时，p不为零；R4表示氢、烷基、烯基、—S（O）2—R8或—C（O）R8，其中R8为烷基、烷氧基；R5和R6各自独立地表示氢、烷基、环烷基或烷氧基；R5和R6可以一起形成3-8成员环，该环可以选择性地包含选自O、S或N的一个或两个杂原子；R7表示氢、可选地从烷基、环烷基、烯基或炔基中选择的取代基。本发明还涉及公式（I）化合物的制备方法，含有公式（I）化合物的制药组合物以及其作为抗糖尿病、降脂、抗肥胖和降胆固醇药物的应用。